리포솜 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Liposomes Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

US $ 4,995 ￦ 7,030,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,267,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,956,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 이번에 세계의 리포솜 시장에 관한 종합 보고서를 발표했습니다. 촉진요인, 새로운 동향, 기회, 과제 등 중요한 시장 역학을 상세히 분석하고, 시장 전망의 상세한 이해를 제공합니다.

주요 인사이트

• 리포솜 시장 규모(2024년) : 75억 6,690만 달러
• 예측 시장 금액(2033년) : 130억 2,960만 달러
• 세계 시장 성장률(CAGR 2024-2033년) : 6.2%

리포솜 시장 - 리포트 범위 :

리포솜은 인지질로 구성된 구형 소포로, 친수성 물질과 소수성 물질을 모두 담을 수 있으며, 약물전달 시스템으로 널리 활용되고 있습니다. 이러한 캐리어는 생체 이용률, 안정성 및 표적 전달을 개선하여 약물의 치료 효과와 안전성을 향상시킵니다. 리포솜 시장은 제약, 화장품, 식품 산업에서 용도가 확대되면서 크게 성장하고 있습니다. 리포솜 기술의 발전, 표적 약물전달 시스템에 대한 수요 증가, 만성질환의 유병률 증가는 시장을 발전시키는 주요 요인입니다.

시장 성장의 촉진요인:

세계 리포솜 시장은 효과적인 약물전달 시스템에 대한 수요 증가, 암 및 심혈관 질환과 같은 만성질환 증가 등 몇 가지 주요 요인에 의해 촉진되고 있습니다. 리포솜 제제의 독성을 낮추고 약물의 표적성을 향상시키는 능력으로 인해 암 치료에서 리포솜 제제에 대한 선호도가 높아지고 있는 것은 중요한 성장 동력이 되고 있습니다. 또한 리포솜 제조 기술의 발전과 화장품 및 건강 보조 식품에 대한 리포솜 적용 확대도 시장 성장에 기여하고 있습니다.

시장 성장 억제요인 :

리포솜 시장은 그 잠재력에도 불구하고 높은 제조 비용과 복잡한 제조 공정 등의 문제에 직면해 있습니다. 리포솜 제제 개발에는 첨단 기술과 전문 지식이 필요하므로 보급이 제한적일 수 있습니다. 또한 규제 장벽과 안전성과 유효성을 보장하기 위한 대규모 임상시험의 필요성도 제조업체들이 직면한 과제에 박차를 가하고 있습니다. 이러한 문제를 해결하기 위해서는 제조 공정의 최적화, 비용 절감, 규제 기준 준수 등의 노력이 필요합니다.

시장 기회 :

리포솜 시장은 기술 발전과 R&D 투자 증가로 인해 큰 성장 기회를 제공합니다. 새로운 리포솜 기반 약물전달 시스템과 유전자 치료 및 면역 치료와 같은 새로운 치료 영역과의 융합은 시장 확대의 새로운 길을 열어줄 것으로 기대됩니다. 맞춤형 의료에 대한 관심이 높아지면서 표적 치료를 위한 리포솜 제제 시장 개척은 시장 기업에게 유리한 기회를 제공할 것입니다. 전략적 제휴, 리포솜 기술 혁신, 새로운 용도 개척은 이러한 기회를 활용하고 시장 성장을 가속하는 데 필수적입니다.

이 보고서에서 다룬 주요 질문

• 세계 리포솜 시장의 성장을 가속하는 주요 요인은 무엇인가?
• 리포솜 기반 약물전달 시스템의 채택을 촉진하는 치료 분야와 용도는?
• 기술의 발전은 리포솜 시장 경쟁 구도를 어떻게 변화시키고 있는가?
• 리포솜 시장의 주요 기업은 어디에 있으며, 경쟁력을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계 리포솜 시장의 새로운 동향과 전망은?

목차

제1장 개요

제2장 시장 개요

• 시장 범위 / 분류
• 시장의 정의 / 범위 / 제한
• 포함 사항·제외 사항

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 제품 혁신 / 개발 동향

제4장 주요 성공 요인

• 프로모션 전략 - 제조업체별
• 제품 채택률 - 주요 통계
• 파이프라인 평가
• 규제 시나리오
• PESTEL 분석
• Porter의 산업 분석

제5장 시장 배경

• 거시경제 요인
• 예측 요인 - 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19와 영향 분석
  • 제품별
  • 용도별
  • 유통 채널별
  • 지역별
• 2024년 시장 시나리오

제7장 세계 시장 수요(금액, 백만 달러) 분석

• 과거 시장 금액(백만 달러) 분석, 2019-2023년
• 현재 및 향후 시장 금액(백만 달러) 분석과 예측, 2024-2033년
  • 전년대비 성장 동향 분석
  • 절대액 기회 분석

제8장 세계 시장 분석 : 제품별

• 서론 / 주요 조사 결과
• 과거 시장 규모(백만 달러) 분석 : 제품별, 2019-2023년
• 현재 및 향후 시장 규모(백만 달러) 분석과 예측 : 제품별, 2024-2033년
  • 단순 리포솜
  • 처방 리포솜
  • 백신
• 시장의 매력 분석 : 제품별

제9장 세계 시장 분석 : 용도별

• 서론 / 주요 조사 결과
• 과거 시장 규모(백만 달러) 분석 : 용도별, 2019-2023년
• 현재 및 향후 시장 규모(백만 달러) 분석과 예측 : 용도별, 2024-2033년
  • 약물전달
  • 유전자 전달 / 트랜스펙션
  • 의료 영상 진단용 조영제
  • 세포막 모델
• 시장의 매력 분석 : 용도별

제10장 세계 시장 분석 : 유통 채널별

• 서론 / 주요 조사 결과
• 과거 시장 규모(백만 달러) 분석 : 유통 채널별, 2019-2023년
• 현재 및 향후 시장 규모(백만 달러) 분석과 예측 : 유통 채널별, 2024-2033년
  • 소매 판매
  • 유통 판매
• 시장의 매력 분석 : 유통 채널별

제11장 세계 시장 분석 : 지역별

• 서론
• 과거 시장 규모(백만 달러) 분석 : 지역별, 2019-2023년
• 현재 및 향후 시장 금액(백만 달러) 분석과 예측 : 지역별, 2024-2033년
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카(MEA)
• 시장의 매력 분석 : 지역별

제12장 북미 시장 분석

제13장 라틴아메리카 시장 분석

제14장 유럽 시장 분석

제15장 동아시아 시장 분석

제16장 남아시아 시장 분석

제17장 오세아니아 시장

제18장 중동 및 아프리카(MEA) 시장 분석

제19장 시장 구조 분석

• 시장 분석 : 기업 계층별
• 주요 기업의 시장 점유율 분석
• 시장 입지 분석

제20장 경쟁 분석

• 경쟁 대시보드
• 브랜딩과 프로모션 전략
• 주요 개발 분석
• 경쟁 상세 정보
  • Novartis AG(Liposoma BV)
  • Precision NanoSystems Inc
  • Janssen Pharmaceutical Companies(Johnson &Johnson)
  • Encapsula Nano Sciences
  • Synpac-Kingdom Pharmaceutical Co., Ltd
  • Celsion GmbH
  • Gilead Sciences, Inc
  • Pacira BioSciences, Inc.
  • Luye Pharma Group
  • Sun Pharma Industries Ltd
  • Shanghai New Asia Pharmaceutical Co., Ltd.
  • ENERGY DELIVERY SOLUTIONs
  • Creative Biolabs
  • Nanovex Biotechnologies SL
  • Insys Therapeutics Inc
  • Fujifilm Holdings Corporation
  • Virpax Pharmaceuticals
  • Azaya Therapeutics
  • Avanti Polar Lipids, Inc.
  • Breath Therapeutics(Zambon company)
  • Getwell
  • Taiwan Liposome Company Ltd
  • Fresenius Health Care Group
  • Xellia Pharmaceuticals(Novo Holdings A/S)
  • Jazz Pharmaceuticals plc
  • Ipsen Biopharmaceuticals, Inc.
  • Baxter
  • GMPriority Pharma
  • SG Biopharm Pvt. Ltd

제21장 사용되는 전제 조건과 두자어

제22장 조사 방법

KSA

영문 목차

영문목차

Persistence Market Research has recently unveiled a comprehensive report on the global Liposomes Market. This report provides an in-depth analysis of critical market dynamics, including driving factors, emerging trends, opportunities, and challenges, offering a detailed understanding of the market landscape.

Key Insights:

• Liposomes Market Size (2024E): USD 7566.9 Mn
• Projected Market Value (2033F): USD 13029.6 Mn
• Global Market Growth Rate (CAGR 2024 to 2033): 6.2%

Liposomes Market - Report Scope:

Liposomes are spherical vesicles composed of phospholipids, which are widely used as drug delivery systems due to their ability to encapsulate both hydrophilic and hydrophobic substances. These carriers enhance the therapeutic efficacy and safety of drugs by improving their bioavailability, stability, and targeted delivery. The liposomes market is witnessing substantial growth driven by their increasing applications in pharmaceuticals, cosmetics, and food industries. Advancements in liposome technology, rising demand for targeted drug delivery systems, and the growing prevalence of chronic diseases are key factors propelling the market forward.

Market Growth Drivers:

The global Liposomes Market is driven by several key factors, including the increasing demand for effective drug delivery systems and the rise in chronic diseases such as cancer and cardiovascular disorders. The growing preference for liposomal formulations in cancer therapy, owing to their ability to reduce toxicity and enhance drug targeting, is a significant growth driver. Additionally, advancements in liposome manufacturing technologies and the expansion of liposome applications in cosmetics and nutraceuticals are contributing to market growth.

Market Restraints:

Despite its potential, the Liposomes Market faces challenges such as high production costs and complex manufacturing processes. The development of liposomal formulations requires sophisticated technology and expertise, which can limit their widespread adoption. Moreover, regulatory hurdles and the need for extensive clinical trials to ensure safety and efficacy add to the challenges faced by manufacturers. Addressing these challenges involves optimizing production processes, reducing costs, and ensuring compliance with regulatory standards.

Market Opportunities:

The Liposomes Market presents significant growth opportunities driven by technological advancements and increasing investment in research and development. The integration of novel liposome-based drug delivery systems with emerging therapeutic areas such as gene therapy and immunotherapy is expected to open new avenues for market expansion. The growing emphasis on personalized medicine and the development of liposomal formulations for targeted therapies offer lucrative opportunities for market players. Strategic collaborations, innovation in liposome technology, and the exploration of new applications are essential for capitalizing on these opportunities and driving market growth.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Liposomes Market globally?
• Which therapeutic areas and applications are leading the adoption of liposome-based drug delivery systems?
• How are technological advancements reshaping the competitive landscape of the Liposomes Market?
• Who are the key players in the Liposomes Market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global Liposomes Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Liposomes Market, such as Gilead Sciences, Inc., Johnson & Johnson, and Novartis AG, focus on innovation, technological advancements, and strategic collaborations to gain a competitive edge. These companies invest heavily in R&D to develop cutting-edge liposomal formulations that offer enhanced drug delivery capabilities and reduced side effects. Partnerships with research institutions, biotechnology firms, and pharmaceutical companies facilitate market access and promote the adoption of liposome-based therapies. Emphasizing patient-centric approaches, robust regulatory compliance, and the development of cost-effective solutions are key strategies for maintaining market leadership in the dynamic Liposomes Market landscape.

Key Companies Profiled:

• Novartis AG (Liposoma BV)
• Precision NanoSystems Inc
• Janssen Pharmaceutical Companies (Johnson & Johnson)
• Encapsula Nano Sciences
• Synpac-Kingdom Pharmaceutical Co., Ltd
• Celsion GmbH
• Gilead Sciences, Inc
• Pacira BioSciences, Inc.
• Luye Pharma Group
• Sun Pharma Industries Ltd
• Shanghai New Asia Pharmaceutical Co., Ltd.
• ENERGY DELIVERY SOLUTIONs
• Creative Biolabs
• Nanovex Biotechnologies SL
• Insys Therapeutics Inc
• Fujifilm Holdings Corporation
• Virpax Pharmaceuticals
• Azaya Therapeutics
• Avanti Polar Lipids, Inc.
• Breath Therapeutics (Zambon company)
• Getwell
• Taiwan Liposome Company Ltd
• Fresenius Health Care Group
• Xellia Pharmaceuticals (Novo Holdings A/S)
• Jazz Pharmaceuticals plc
• Ipsen Biopharmaceuticals, Inc.
• Baxter
• GMPriority Pharma
• S. G. Biopharm Pvt. Ltd

Key Segments Covered in Liposomes Industry Research

Product:

• Simple Liposomes
• Formulated Liposomes
• Vaccines

Application:

• Drug delivery
• Gene Delivery/Transfection
• Contrast agents for medical imaging
• Model Cell Membranes

Distribution Channel:

• Retail Sales
• Distributional Sales

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Promotional Strategies - By Manufacturers
• 4.2. Product Adoption Rate - Key Statistics
• 4.3. Pipeline Assessment
• 4.4. Regulatory Scenario
• 4.5. PESTEL Analysis
• 4.6. Porter's Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
  • 5.1.3. Global Drug Delivery Systems Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Prevalence of Chronic Diseases
  • 5.2.2. Growing Demand for Liposomal Drugs
  • 5.2.3. Widespread Adoption as Nano - Carriers for Diverse Pharmaceutical Applications
  • 5.2.4. Increasing Research and Development Activities
  • 5.2.5. Technological Advancements
  • 5.2.6. Merger and Acquisitions
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Product
  • 6.1.2. By Application
  • 6.1.3. By Distribution Channel
  • 6.1.4. By Region
• 6.2. 2024 Market Scenario

7. Global Market Demand (in Value US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Analysis and Forecast, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Product

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis, by Product, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Product, 2024-2033
  • 8.3.1. Simple Liposomes
  • 8.3.2. Formulated Liposomes
    • 8.3.2.1. Doxorubicin Liposomes
    • 8.3.2.2. Amphotericin B Liposomes
    • 8.3.2.3. Paclitaxel Liposomes
    • 8.3.2.4. Cytarabine Liposomes
    • 8.3.2.5. Irinotecan Liposomes
    • 8.3.2.6. Cisplatin Liposomes
    • 8.3.2.7. Others
  • 8.3.3. Vaccines
• 8.4. Market Attractiveness Analysis, by Product

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Application

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Application, 2024-2033
  • 9.3.1. Drug delivery
    • 9.3.1.1. Cancer
    • 9.3.1.2. Fungal Infection
    • 9.3.1.3. Viral & Parasite Infection
    • 9.3.1.4. Others
  • 9.3.2. Gene Delivery/Transfection
  • 9.3.3. Contrast agents for medical imaging
  • 9.3.4. Model Cell Membranes
• 9.4. Market Attractiveness Analysis, by Application

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Distribution Channel, 2024-2033
  • 10.3.1. Retail Sales
    • 10.3.1.1. Academic & Research Laboratories
    • 10.3.1.2. Biopharmaceutical Companies
    • 10.3.1.3. Clinical Research Organizations
    • 10.3.1.4. Others
  • 10.3.2. Distributional Sales
    • 10.3.2.1. Hospital Pharmacies
    • 10.3.2.2. Retail Pharmacies
    • 10.3.2.3. Mail Order Pharmacies
    • 10.3.2.4. Drug Stores
• 10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) Analysis, by Region, 2019-2023
• 11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Region 2024-2033
  • 11.3.1. North America
  • 11.3.2. Latin America
  • 11.3.3. Europe
  • 11.3.4. East Asia
  • 11.3.5. South Asia
  • 11.3.6. Oceania
  • 11.3.7. Middle East and Africa (MEA)
• 11.4. Market Attractiveness Analysis, by Region

12. North America Market Analysis 2019-2023 and Forecast 2024-2033

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
  • 12.3.1. By Country
    • 12.3.1.1. U.S.
    • 12.3.1.2. Canada
  • 12.3.2. By Product
  • 12.3.3. By Application
  • 12.3.4. By Distribution Channel
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Product
  • 12.4.3. By Application
  • 12.4.4. By Distribution Channel
• 12.5. Market Trends
• 12.6. Drivers and Restraints - Impact Analysis
• 12.7. Country Level Analysis & Forecast
  • 12.7.1. U.S. Market Analysis
    • 12.7.1.1. Introduction
    • 12.7.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 12.7.1.2.1. By Product
      • 12.7.1.2.2. By Application
      • 12.7.1.2.3. By Distribution Channel
  • 12.7.2. Canada Market Analysis
    • 12.7.2.1. Introduction
    • 12.7.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 12.7.2.2.1. By Product
      • 12.7.2.2.2. By Application
      • 12.7.2.2.3. By Distribution Channel

13. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. Mexico
    • 13.3.1.2. Brazil
    • 13.3.1.3. Argentina
    • 13.3.1.4. Rest of Latin America
  • 13.3.2. By Product
  • 13.3.3. By Application
  • 13.3.4. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Product
  • 13.4.3. By Application
  • 13.4.4. By Distribution Channel
• 13.5. Market Trends
• 13.6. Drivers and Restraints - Impact Analysis
• 13.7. Country Level Analysis & Forecast
  • 13.7.1. Mexico Market Analysis
    • 13.7.1.1. Introduction
    • 13.7.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 13.7.1.2.1. By Product
      • 13.7.1.2.2. By Application
      • 13.7.1.2.3. By Distribution Channel
  • 13.7.2. Brazil Market Analysis
    • 13.7.2.1. Introduction
    • 13.7.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 13.7.2.2.1. By Product
      • 13.7.2.2.2. By Application
      • 13.7.2.2.3. By Distribution Channel
  • 13.7.3. Argentina Market Analysis
    • 13.7.3.1. Introduction
    • 13.7.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 13.7.3.2.1. By Product
      • 13.7.3.2.2. By Application
      • 13.7.3.2.3. By Distribution Channel

14. Europe Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. Germany
    • 14.3.1.2. Italy
    • 14.3.1.3. France
    • 14.3.1.4. U.K.
    • 14.3.1.5. Spain
    • 14.3.1.6. BENELUX
    • 14.3.1.7. Russia
    • 14.3.1.8. Rest of Europe
  • 14.3.2. By Product
  • 14.3.3. By Application
  • 14.3.4. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Product
  • 14.4.3. By Application
  • 14.4.4. By Distribution Channel
• 14.5. Market Trends
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Country Level Analysis & Forecast
  • 14.7.1. Germany Market Analysis
    • 14.7.1.1. Introduction
    • 14.7.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.7.1.2.1. By Product
      • 14.7.1.2.2. By Application
      • 14.7.1.2.3. By Distribution Channel
  • 14.7.2. Italy Market Analysis
    • 14.7.2.1. Introduction
    • 14.7.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.7.2.2.1. By Product
      • 14.7.2.2.2. By Application
      • 14.7.2.2.3. By Distribution Channel
  • 14.7.3. France Market Analysis
    • 14.7.3.1. Introduction
    • 14.7.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.7.3.2.1. By Product
      • 14.7.3.2.2. By Application
      • 14.7.3.2.3. By Distribution Channel
  • 14.7.4. U.K. Market Analysis
    • 14.7.4.1. Introduction
    • 14.7.4.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.7.4.2.1. By Product
      • 14.7.4.2.2. By Application
      • 14.7.4.2.3. By Distribution Channel
  • 14.7.5. Spain Market Analysis
    • 14.7.5.1. Introduction
    • 14.7.5.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.7.5.2.1. By Product
      • 14.7.5.2.2. By Application
      • 14.7.5.2.3. By Distribution Channel
  • 14.7.6. BENELUX Market Analysis
    • 14.7.6.1. Introduction
    • 14.7.6.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.7.6.2.1. By Product
      • 14.7.6.2.2. By Application
      • 14.7.6.2.3. By Distribution Channel
  • 14.7.7. Russia Market Analysis
    • 14.7.7.1. Introduction
    • 14.7.7.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.7.7.2.1. By Product
      • 14.7.7.2.2. By Application
      • 14.7.7.2.3. By Distribution Channel

15. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Distribution Channel (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. China
    • 15.3.1.2. Japan
    • 15.3.1.3. South Korea
  • 15.3.2. By Product
  • 15.3.3. By Application
  • 15.3.4. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Product
  • 15.4.2. By Application
  • 15.4.3. By Distribution Channel
• 15.5. Market Trends
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Country Level Analysis & Forecast
  • 15.7.1. China Market Analysis
    • 15.7.1.1. Introduction
    • 15.7.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.7.1.2.1. By Product
      • 15.7.1.2.2. By Application
      • 15.7.1.2.3. By Distribution Channel
  • 15.7.2. Japan Market Analysis
    • 15.7.2.1. Introduction
    • 15.7.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.7.2.2.1. By Product
      • 15.7.2.2.2. By Application
      • 15.7.2.2.3. By Distribution Channel
  • 15.7.3. South Korea Market Analysis
    • 15.7.3.1. Introduction
    • 15.7.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.7.3.2.1. By Product
      • 15.7.3.2.2. By Application
      • 15.7.3.2.3. By Distribution Channel

16. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Indonesia
    • 16.3.1.3. Malaysia
    • 16.3.1.4. Thailand
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By Product
  • 16.3.3. By Application
  • 16.3.4. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Product
  • 16.4.3. By Application
  • 16.4.4. By Distribution Channel
• 16.5. Market Trends
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Country Level Analysis & Forecast
  • 16.7.1. India Market Analysis
    • 16.7.1.1. Introduction
    • 16.7.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.7.1.2.1. By Product
      • 16.7.1.2.2. By Application
      • 16.7.1.2.3. By Distribution Channel
  • 16.7.2. Indonesia Market Analysis
    • 16.7.2.1. Introduction
    • 16.7.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.7.2.2.1. By Product
      • 16.7.2.2.2. By Application
      • 16.7.2.2.3. By Distribution Channel
  • 16.7.3. Malaysia Market Analysis
    • 16.7.3.1. Introduction
    • 16.7.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.7.3.2.1. By Product
      • 16.7.3.2.2. By Application
      • 16.7.3.2.3. By Distribution Channel
  • 16.7.4. Thailand Market Analysis
    • 16.7.4.1. Introduction
    • 16.7.4.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.7.4.2.1. By Product
      • 16.7.4.2.2. By Application
      • 16.7.4.2.3. By Distribution Channel

17. Oceania Market 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. Australia
    • 17.3.1.2. New Zealand
  • 17.3.2. By Product
  • 17.3.3. By Application
  • 17.3.4. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Product
  • 17.4.3. By Application
  • 17.4.4. By Distribution Channel
• 17.5. Market Trends
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Country Level Analysis & Forecast
  • 17.7.1. Australia Market Analysis
    • 17.7.1.1. Introduction
    • 17.7.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 17.7.1.2.1. By Product
      • 17.7.1.2.2. By Application
      • 17.7.1.2.3. By Distribution Channel
  • 17.7.2. New Zealand Market Analysis
    • 17.7.2.1. Introduction
    • 17.7.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 17.7.2.2.1. By Product
      • 17.7.2.2.2. By Application
      • 17.7.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Trend Analysis, by Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy 2024-2033
  • 18.3.1. By Country
    • 18.3.1.1. GCC Countries
    • 18.3.1.2. Turkiye
    • 18.3.1.3. South Africa
    • 18.3.1.4. North Africa
    • 18.3.1.5. Rest of Middle East and Africa
  • 18.3.2. By Product
  • 18.3.3. By Application
  • 18.3.4. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Product
  • 18.4.2. By Application
  • 18.4.3. By Distribution Channel
• 18.5. Market Trends
• 18.6. Drivers and Restraints - Impact Analysis
• 18.7. Country Level Analysis & Forecast
  • 18.7.1. GCC Countries Market Analysis
    • 18.7.1.1. Introduction
    • 18.7.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 18.7.1.2.1. By Product
      • 18.7.1.2.2. By Application
      • 18.7.1.2.3. By Distribution Channel
  • 18.7.2. Turkiye Market Analysis
    • 18.7.2.1. Introduction
    • 18.7.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 18.7.2.2.1. By Product
      • 18.7.2.2.2. By Application
      • 18.7.2.2.3. By Distribution Channel
  • 18.7.3. South Africa Market Analysis
    • 18.7.3.1. Introduction
    • 18.7.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 18.7.3.2.1. By Product
      • 18.7.3.2.2. By Application
      • 18.7.3.2.3. By Distribution Channel
  • 18.7.4. North Africa Market Analysis
    • 18.7.4.1. Introduction
    • 18.7.4.2. Market Analysis and Forecast, by Market Taxonomy
      • 18.7.4.2.1. By Product
      • 18.7.4.2.2. By Application
      • 18.7.4.2.3. By Distribution Channel

19. Market Structure Analysis

• 19.1. Market Analysis, by Tier of Companies
• 19.2. Market Share Analysis of Top Players
• 19.3. Market Presence Analysis

20. Competition Analysis

• 20.1. Competition Dashboard
• 20.2. Branding and Promotional Strategies
• 20.3. Key Development Analysis
• 20.4. Competition Deep Dive
  • 20.4.1. Novartis AG (Liposoma BV)
    • 20.4.1.1. Overview
    • 20.4.1.2. Product Portfolio
    • 20.4.1.3. Sales Footprint
    • 20.4.1.4. Key Financials
    • 20.4.1.5. SWOT Analysis
    • 20.4.1.6. Strategy Overview
      • 20.4.1.6.1. Marketing Strategy
      • 20.4.1.6.2. Product Strategy
      • 20.4.1.6.3. Channel Strategy
  • 20.4.2. Precision NanoSystems Inc
    • 20.4.2.1. Overview
    • 20.4.2.2. Product Portfolio
    • 20.4.2.3. Sales Footprint
    • 20.4.2.4. Key Financials
    • 20.4.2.5. SWOT Analysis
    • 20.4.2.6. Strategy Overview
      • 20.4.2.6.1. Marketing Strategy
      • 20.4.2.6.2. Product Strategy
      • 20.4.2.6.3. Channel Strategy
  • 20.4.3. Janssen Pharmaceutical Companies (Johnson & Johnson)
    • 20.4.3.1. Overview
    • 20.4.3.2. Product Portfolio
    • 20.4.3.3. Sales Footprint
    • 20.4.3.4. Key Financials
    • 20.4.3.5. SWOT Analysis
    • 20.4.3.6. Strategy Overview
      • 20.4.3.6.1. Marketing Strategy
      • 20.4.3.6.2. Product Strategy
      • 20.4.3.6.3. Channel Strategy
  • 20.4.4. Encapsula Nano Sciences
    • 20.4.4.1. Overview
    • 20.4.4.2. Product Portfolio
    • 20.4.4.3. Sales Footprint
    • 20.4.4.4. Key Financials
    • 20.4.4.5. SWOT Analysis
    • 20.4.4.6. Strategy Overview
      • 20.4.4.6.1. Marketing Strategy
      • 20.4.4.6.2. Product Strategy
      • 20.4.4.6.3. Channel Strategy
  • 20.4.5. Synpac-Kingdom Pharmaceutical Co., Ltd
    • 20.4.5.1. Overview
    • 20.4.5.2. Product Portfolio
    • 20.4.5.3. Sales Footprint
    • 20.4.5.4. Key Financials
    • 20.4.5.5. SWOT Analysis
    • 20.4.5.6. Strategy Overview
      • 20.4.5.6.1. Marketing Strategy
      • 20.4.5.6.2. Product Strategy
      • 20.4.5.6.3. Channel Strategy
  • 20.4.6. Celsion GmbH
    • 20.4.6.1. Overview
    • 20.4.6.2. Product Portfolio
    • 20.4.6.3. Sales Footprint
    • 20.4.6.4. Key Financials
    • 20.4.6.5. SWOT Analysis
    • 20.4.6.6. Strategy Overview
      • 20.4.6.6.1. Marketing Strategy
      • 20.4.6.6.2. Product Strategy
      • 20.4.6.6.3. Channel Strategy
  • 20.4.7. Gilead Sciences, Inc
    • 20.4.7.1. Overview
    • 20.4.7.2. Product Portfolio
    • 20.4.7.3. Sales Footprint
    • 20.4.7.4. Key Financials
    • 20.4.7.5. SWOT Analysis
    • 20.4.7.6. Strategy Overview
      • 20.4.7.6.1. Marketing Strategy
      • 20.4.7.6.2. Product Strategy
      • 20.4.7.6.3. Channel Strategy
  • 20.4.8. Pacira BioSciences, Inc.
    • 20.4.8.1. Overview
    • 20.4.8.2. Product Portfolio
    • 20.4.8.3. Sales Footprint
    • 20.4.8.4. Key Financials
    • 20.4.8.5. SWOT Analysis
    • 20.4.8.6. Strategy Overview
      • 20.4.8.6.1. Marketing Strategy
      • 20.4.8.6.2. Product Strategy
      • 20.4.8.6.3. Channel Strategy
  • 20.4.9. Luye Pharma Group
    • 20.4.9.1. Overview
    • 20.4.9.2. Product Portfolio
    • 20.4.9.3. Sales Footprint
    • 20.4.9.4. Key Financials
    • 20.4.9.5. SWOT Analysis
    • 20.4.9.6. Strategy Overview
      • 20.4.9.6.1. Marketing Strategy
      • 20.4.9.6.2. Product Strategy
      • 20.4.9.6.3. Channel Strategy
  • 20.4.10. Sun Pharma Industries Ltd
    • 20.4.10.1. Overview
    • 20.4.10.2. Product Portfolio
    • 20.4.10.3. Sales Footprint
    • 20.4.10.4. Key Financials
    • 20.4.10.5. SWOT Analysis
    • 20.4.10.6. Strategy Overview
      • 20.4.10.6.1. Marketing Strategy
      • 20.4.10.6.2. Product Strategy
      • 20.4.10.6.3. Channel Strategy
  • 20.4.11. Shanghai New Asia Pharmaceutical Co., Ltd.
    • 20.4.11.1. Overview
    • 20.4.11.2. Product Portfolio
    • 20.4.11.3. Sales Footprint
    • 20.4.11.4. Key Financials
    • 20.4.11.5. SWOT Analysis
    • 20.4.11.6. Strategy Overview
      • 20.4.11.6.1. Marketing Strategy
      • 20.4.11.6.2. Product Strategy
      • 20.4.11.6.3. Channel Strategy
  • 20.4.12. ENERGY DELIVERY SOLUTIONs
    • 20.4.12.1. Overview
    • 20.4.12.2. Product Portfolio
    • 20.4.12.3. Sales Footprint
    • 20.4.12.4. Key Financials
    • 20.4.12.5. SWOT Analysis
    • 20.4.12.6. Strategy Overview
      • 20.4.12.6.1. Marketing Strategy
      • 20.4.12.6.2. Product Strategy
      • 20.4.12.6.3. Channel Strategy
  • 20.4.13. Creative Biolabs
    • 20.4.13.1. Overview
    • 20.4.13.2. Product Portfolio
    • 20.4.13.3. Sales Footprint
    • 20.4.13.4. Key Financials
    • 20.4.13.5. SWOT Analysis
    • 20.4.13.6. Strategy Overview
      • 20.4.13.6.1. Marketing Strategy
      • 20.4.13.6.2. Product Strategy
      • 20.4.13.6.3. Channel Strategy
  • 20.4.14. Nanovex Biotechnologies SL
    • 20.4.14.1. Overview
    • 20.4.14.2. Product Portfolio
    • 20.4.14.3. Sales Footprint
    • 20.4.14.4. Key Financials
    • 20.4.14.5. SWOT Analysis
    • 20.4.14.6. Strategy Overview
      • 20.4.14.6.1. Marketing Strategy
      • 20.4.14.6.2. Product Strategy
      • 20.4.14.6.3. Channel Strategy
  • 20.4.15. Insys Therapeutics Inc
    • 20.4.15.1. Overview
    • 20.4.15.2. Product Portfolio
    • 20.4.15.3. Sales Footprint
    • 20.4.15.4. Key Financials
    • 20.4.15.5. SWOT Analysis
    • 20.4.15.6. Strategy Overview
      • 20.4.15.6.1. Marketing Strategy
      • 20.4.15.6.2. Product Strategy
      • 20.4.15.6.3. Channel Strategy
  • 20.4.16. Fujifilm Holdings Corporation
    • 20.4.16.1. Overview
    • 20.4.16.2. Product Portfolio
    • 20.4.16.3. Sales Footprint
    • 20.4.16.4. Key Financials
    • 20.4.16.5. SWOT Analysis
    • 20.4.16.6. Strategy Overview
      • 20.4.16.6.1. Marketing Strategy
      • 20.4.16.6.2. Product Strategy
      • 20.4.16.6.3. Channel Strategy
  • 20.4.17. Virpax Pharmaceuticals
    • 20.4.17.1. Overview
    • 20.4.17.2. Product Portfolio
    • 20.4.17.3. Sales Footprint
    • 20.4.17.4. Key Financials
    • 20.4.17.5. SWOT Analysis
    • 20.4.17.6. Strategy Overview
      • 20.4.17.6.1. Marketing Strategy
      • 20.4.17.6.2. Product Strategy
      • 20.4.17.6.3. Channel Strategy
  • 20.4.18. Azaya Therapeutics
    • 20.4.18.1. Overview
    • 20.4.18.2. Product Portfolio
    • 20.4.18.3. Sales Footprint
    • 20.4.18.4. Key Financials
    • 20.4.18.5. SWOT Analysis
    • 20.4.18.6. Strategy Overview
      • 20.4.18.6.1. Marketing Strategy
      • 20.4.18.6.2. Product Strategy
      • 20.4.18.6.3. Channel Strategy
  • 20.4.19. Avanti Polar Lipids, Inc.
    • 20.4.19.1. Overview
    • 20.4.19.2. Product Portfolio
    • 20.4.19.3. Sales Footprint
    • 20.4.19.4. Key Financials
    • 20.4.19.5. SWOT Analysis
    • 20.4.19.6. Strategy Overview
      • 20.4.19.6.1. Marketing Strategy
      • 20.4.19.6.2. Product Strategy
      • 20.4.19.6.3. Channel Strategy
  • 20.4.20. Breath Therapeutics (Zambon company)
    • 20.4.20.1. Overview
    • 20.4.20.2. Product Portfolio
    • 20.4.20.3. Sales Footprint
    • 20.4.20.4. Key Financials
    • 20.4.20.5. SWOT Analysis
    • 20.4.20.6. Strategy Overview
      • 20.4.20.6.1. Marketing Strategy
      • 20.4.20.6.2. Product Strategy
      • 20.4.20.6.3. Channel Strategy
  • 20.4.21. Getwell
    • 20.4.21.1. Overview
    • 20.4.21.2. Product Portfolio
    • 20.4.21.3. Sales Footprint
    • 20.4.21.4. Key Financials
    • 20.4.21.5. SWOT Analysis
    • 20.4.21.6. Strategy Overview
      • 20.4.21.6.1. Marketing Strategy
      • 20.4.21.6.2. Product Strategy
      • 20.4.21.6.3. Channel Strategy
  • 20.4.22. Taiwan Liposome Company Ltd
    • 20.4.22.1. Overview
    • 20.4.22.2. Product Portfolio
    • 20.4.22.3. Sales Footprint
    • 20.4.22.4. Key Financials
    • 20.4.22.5. SWOT Analysis
    • 20.4.22.6. Strategy Overview
      • 20.4.22.6.1. Marketing Strategy
      • 20.4.22.6.2. Product Strategy
      • 20.4.22.6.3. Channel Strategy
  • 20.4.23. Fresenius Health Care Group
    • 20.4.23.1. Overview
    • 20.4.23.2. Product Portfolio
    • 20.4.23.3. Sales Footprint
    • 20.4.23.4. Key Financials
    • 20.4.23.5. SWOT Analysis
    • 20.4.23.6. Strategy Overview
      • 20.4.23.6.1. Marketing Strategy
      • 20.4.23.6.2. Product Strategy
      • 20.4.23.6.3. Channel Strategy
  • 20.4.24. Xellia Pharmaceuticals (Novo Holdings A/S)
    • 20.4.24.1. Overview
    • 20.4.24.2. Product Portfolio
    • 20.4.24.3. Sales Footprint
    • 20.4.24.4. Key Financials
    • 20.4.24.5. SWOT Analysis
    • 20.4.24.6. Strategy Overview
      • 20.4.24.6.1. Marketing Strategy
      • 20.4.24.6.2. Product Strategy
      • 20.4.24.6.3. Channel Strategy
  • 20.4.25. Jazz Pharmaceuticals plc
    • 20.4.25.1. Overview
    • 20.4.25.2. Product Portfolio
    • 20.4.25.3. Sales Footprint
    • 20.4.25.4. Key Financials
    • 20.4.25.5. SWOT Analysis
    • 20.4.25.6. Strategy Overview
      • 20.4.25.6.1. Marketing Strategy
      • 20.4.25.6.2. Product Strategy
      • 20.4.25.6.3. Channel Strategy
  • 20.4.26. Ipsen Biopharmaceuticals, Inc.
    • 20.4.26.1. Overview
    • 20.4.26.2. Product Portfolio
    • 20.4.26.3. Sales Footprint
    • 20.4.26.4. Key Financials
    • 20.4.26.5. SWOT Analysis
    • 20.4.26.6. Strategy Overview
      • 20.4.26.6.1. Marketing Strategy
      • 20.4.26.6.2. Product Strategy
      • 20.4.26.6.3. Channel Strategy
  • 20.4.27. Baxter
    • 20.4.27.1. Overview
    • 20.4.27.2. Product Portfolio
    • 20.4.27.3. Sales Footprint
    • 20.4.27.4. Key Financials
    • 20.4.27.5. SWOT Analysis
    • 20.4.27.6. Strategy Overview
      • 20.4.27.6.1. Marketing Strategy
      • 20.4.27.6.2. Product Strategy
      • 20.4.27.6.3. Channel Strategy
  • 20.4.28. GMPriority Pharma
    • 20.4.28.1. Overview
    • 20.4.28.2. Product Portfolio
    • 20.4.28.3. Sales Footprint
    • 20.4.28.4. Key Financials
    • 20.4.28.5. SWOT Analysis
    • 20.4.28.6. Strategy Overview
      • 20.4.28.6.1. Marketing Strategy
      • 20.4.28.6.2. Product Strategy
      • 20.4.28.6.3. Channel Strategy
  • 20.4.29. S. G. Biopharm Pvt. Ltd
    • 20.4.29.1. Overview
    • 20.4.29.2. Product Portfolio
    • 20.4.29.3. Sales Footprint
    • 20.4.29.4. Key Financials
    • 20.4.29.5. SWOT Analysis
    • 20.4.29.6. Strategy Overview
      • 20.4.29.6.1. Marketing Strategy
      • 20.4.29.6.2. Product Strategy
      • 20.4.29.6.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

관련자료